Four cancer cases with pathological germline variant RAD51D c.270_271dup

被引:0
|
作者
Ishihara, Eiko [1 ]
Matsubayashi, Hiroyuki [1 ,2 ]
Nishimura, Seiichiro [1 ,3 ]
Isaka, Mitsuhiro [4 ]
Konno, Hayato [4 ]
Goto, Seiya [5 ]
Yamaguchi, Ken [6 ]
Urakami, Kenichi [6 ]
机构
[1] Shizuoka Canc Ctr, Div Genet Med Promot, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Div Endoscopy, Shizuoka, Japan
[3] Shizuoka Canc Ctr, Div Breast Surg, Shizuoka, Japan
[4] Shizuoka Canc Ctr, Div Resp Surg, Shizuoka, Japan
[5] Shizuoka Canc Ctr, Div Head & Neck Surg, Shizuoka, Japan
[6] Shizuoka Canc Ctr, Div Clin Res Ctr, Shizuoka, Japan
关键词
cancer risk; germline; moderate-risk cancer gene; RAD51D 270_271dup; MUTATIONS;
D O I
10.1111/jog.16045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Pathological germline variants (PGVs) of RAD51D increase the risk of breast and ovarian cancer. In East Asia, c.270_271dup is the most frequently detected PGV of RAD51D; however, only a few cases have been reported in Japan. We report four cancer cases with a germline RAD51D c.270_271dup PGV. Three of them (lung cancer: 2, oral cancer: 1) were incidentally identified by whole genome sequencing in patients negative for the associated cancer histories, homologous recombination (HR) deficiency, or a second hit of RAD51D in the cancer DNA. For genetic counseling, we provided information on surveillance and cascade testing based on Western guidelines. The PGVs of moderate-risk HR-related genes are difficult to detect based on phenotype, especially in male-predominant pedigrees. The current spread of cancer genomic analysis will increase opportunities for incidental variant identification. The establishment of Japanese guidelines is expected to aid in the management of PGV carriers of moderate-risk genes.
引用
收藏
页码:1742 / 1747
页数:6
相关论文
共 8 条
  • [1] A decade of RAD51C and RAD51D germline variants in cancer
    Boni, Jacopo
    Idani, Aida
    Roca, Carla
    Feliubadalo, Lidia
    Tomiak, Eva
    Weber, Evan
    Foulkes, William D.
    Orthwein, Alexandre
    El Haffaf, Zaki
    Lazaro, Conxi
    Rivera, Barbara
    HUMAN MUTATION, 2022, 43 (03) : 285 - 298
  • [2] Germline mutations in RAD51D confer susceptibility to ovarian cancer
    Loveday, Chey
    Turnbull, Clare
    Ramsay, Emma
    Hughes, Deborah
    Ruark, Elise
    Frankum, Jessica R.
    Bowden, Georgina
    Kalmyrzaev, Bolot
    Warren-Perry, Margaret
    Snape, Katie
    Adlard, Julian W.
    Barwell, Julian
    Berg, Jonathan
    Brady, Angela F.
    Brewer, Carole
    Brice, Glen
    Chapman, Cyril
    Cook, Jackie
    Davidson, Rosemarie
    Donaldson, Alan
    Douglas, Fiona
    Greenhalgh, Lynn
    Henderson, Alex
    Izatt, Louise
    Kumar, Ajith
    Lalloo, Fiona
    Miedzybrodzka, Zosia
    Morrison, Patrick J.
    Paterson, Joan
    Porteous, Mary
    Rogers, Mark T.
    Shanley, Susan
    Walker, Lisa
    Eccles, Diana
    Evans, D. Gareth
    Renwick, Anthony
    Seal, Sheila
    Lord, Christopher J.
    Ashworth, Alan
    Reis-Filho, Jorge S.
    Antoniou, Antonis C.
    Rahman, Nazneen
    NATURE GENETICS, 2011, 43 (09) : 879 - U90
  • [3] Germline genetic variants in a case of familial cancer: RAD51D and four other co-segregated variants
    Biswas, Shristi
    Manekar, Swati
    Kantharia, Shehnaz
    Bakshi, Sonal
    JOURNAL OF GENETICS, 2024, 103 (02)
  • [4] Retroperitoneal leiomyosarcoma in a female patient with a germline splicing variant RAD51D c.904-2A > T: a case report
    Futagawa, Mashu
    Yamamoto, Hideki
    Kochi, Mariko
    Urakawa, Yusaku
    Sogawa, Reimi
    Kato, Fumino
    Okazawa-Sakai, Mika
    Ennishi, Daisuke
    Shinozaki, Katsunori
    Inoue, Hirofumi
    Yanai, Hiroyuki
    Hirasawa, Akira
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2021, 19 (01)
  • [5] The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population
    Alenezi, Wejdan M.
    Milano, Larissa
    Fierheller, Caitlin T.
    Serruya, Corinne
    Revil, Timothee
    Oros, Kathleen K.
    Behl, Supriya
    Arcand, Suzanna L.
    Nayar, Porangana
    Spiegelman, Dan
    Gravel, Simon
    Mes-Masson, Anne-Marie
    Provencher, Diane
    Foulkes, William D.
    El Haffaf, Zaki
    Rouleau, Guy
    Bouchard, Luigi
    Greenwood, Celia M. T.
    Masson, Jean-Yves
    Ragoussis, Jiannis
    Tonin, Patricia N.
    CANCERS, 2022, 14 (09)
  • [6] Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
    Torres-Esquius, Sara
    Llop-Guevara, Alba
    Gutierrez-Enriquez, Sara
    Romey, Marcel
    Teule, Alex
    Llort, Gemma
    Herrero, Ana
    Sanchez-Henarejos, Pilar
    Vallmajo, Anna
    Gonzalez-Santiago, Santiago
    Chirivella, Isabel
    Cano, Juana Maria
    Grana, Begona
    Simonetti, Sara
    de Corcuera, Isabela Diaz
    Ramon y Cajal, Teresa
    Sanz, Judit
    Serrano, Sara
    Otero, Andrea
    Churruca, Cristina
    Sanchez-Heras, Ana Beatriz
    Servitja, Sonia
    Guillen-Ponce, Carmen
    Brunet, Joan
    Denkert, Carsten
    Serra, Violeta
    Balmana, Judith
    JAMA NETWORK OPEN, 2024, 7 (04)
  • [7] What About the Others? Clinical Management of Gynecologic Cancer Risk in Patients With Moderate-Risk Hereditary Cancer Genes (ATM, BRIP1, RAD51C, RAD51D, and PALB2)
    Goldfeld, Ester I.
    Kelly, Brianna E.
    Ring, Kari L.
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2024, 67 (04) : 696 - 701
  • [8] Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
    Vysotskaia, Valentina
    Kaseniit, K. Eerik
    Bucheit, Leslie
    Ready, Kaylene
    Price, Kristin
    Taber, Katherine Johansen
    CANCER, 2020, 126 (03) : 549 - 558